HER2-Negative Breast Carcinoma Clinical Trials

27 recruitingLast updated: June 17, 2026

There are 27 actively recruiting her2-negative breast carcinoma clinical trials across 28 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


HER2-Negative Breast Carcinoma Trials at a Glance

27 actively recruiting trials for her2-negative breast carcinoma are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in New York, Boston, and Atlanta. Lead sponsors running her2-negative breast carcinoma studies include Mayo Clinic, Emory University, and National Cancer Institute (NCI).

Browse her2-negative breast carcinoma trials by phase

Treatments under study

About HER2-Negative Breast Carcinoma Clinical Trials

Looking for clinical trials for HER2-Negative Breast Carcinoma? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-Negative Breast Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-Negative Breast Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 3

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled19 locationsNCT07391774
Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled541 locationsNCT06058377
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+2 more
Memorial Sloan Kettering Cancer Center176 enrolled7 locationsNCT07483307
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 1

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Not Applicable

Mobile Health for Adherence in Breast Cancer Patients

Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled506 locationsNCT06112613
Recruiting
Phase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Metastatic Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor-positive Breast Cancer+1 more
Mayo Clinic35 enrolled1 locationNCT06525766
Recruiting
Phase 2

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Breast CancerNode-positive Breast CancerHER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center32 enrolled1 locationNCT07276880
Recruiting
Phase 2

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
City of Hope Medical Center174 enrolled3 locationsNCT06042569
Recruiting
Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting
Phase 2

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington40 enrolled1 locationNCT07112053
Recruiting
Phase 2

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic40 enrolled1 locationNCT06450873
Recruiting
Phase 3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Not Applicable

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Ohio State University Comprehensive Cancer Center40 enrolled2 locationsNCT05677802
Recruiting
Not Applicable

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University150 enrolled4 locationsNCT06534125
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticHER2-Negative Breast CarcinomaPancreatic Cancer+17 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+3 more
University of California, San Francisco100 enrolled1 locationNCT06774027